Extrachromosomal gene amplification refers to copy number gains of DNA fragments that are not contiguous with the twenty-three canonical chromosomes. Unlike typical chromosomes, they are composed of circular DNA fragments without centromeric sequences \[[@R1]\]. They arose through complex genomic rearrangements during carcinogenesis and commonly harbor oncogenes, conferring selective advantage for tumor growth and survival \[[@R2]\]. Such extrachromosomal elements, often referred to as double minutes, are frequently observed throughout different types of cancer, especially in glioblastoma \[[@R3]\]. They are dynamically regulated and play important roles in acquired therapeutic resistance \[[@R4]\] and clonal evolution \[[@R3]\].

Epidermal growth factor receptor gene (*EGFR*) is, by far, the most commonly altered oncogene in glioblastomas, the most common form of primary brain cancer. It is mutated or amplified in 60% of glioblastomas \[[@R5]\]. Oncogenic activation of EGFR appears to preferentially occur through deletion of exons two to seven, generating a constitutively activated receptor termed EGFRvIII. Up to 30% of glioblastomas harbor EGFRvIII. Importantly, EGFRvIII is always accompanied by amplification of the full-length *EGFR* gene. EGFRvIII-positive glioblastomas exhibit unique molecular physiologies associated with distinct therapeutic response profiles and an overall tumor aggressiveness \[[@R6]\].

Breakpoint junctions in EGFRvIII are highly variable between tumor samples due to 120-kb-long intron one of this gene where one of the breaks take place. Breakpoint sequence analyses implicate contribution by multiple DNA strand-break repair mechanisms, including non-homologous end joining, micro-homology mediated end joining, and other forms of replication mediated repair \[[@R7]\]. These findings suggest DNA strand breaks as a likely intermediate structure for the *EGFR* deletion variants.

Another interesting observation pertaining to *EGFRvIII* is that a single tumor can harbor multiple, independent *EGFRvIII* variants \-- each with distinct breakpoint junctions. These variants as well as the accompanied amplified full-length EGFR share common allelic profiles, suggesting that the deleted variants arose from a common ancestral amplified *EGFR*. A corollary of this hypothesis is that distinct additional genomic rearrangements of amplified full-length *EGFR* in glioblastoma subpopulations gave rise to polyclonal *EGFRvIII* breakpoint species (Figure [1](#F1){ref-type="fig"}).
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Models for generation of heterogeneous *EGFRvIII* breakpoints through genomic rearrangements. Cells with extrachromosomal amplifications of *EGFR* undergo further independent genomic rearrangements resulting in heterogeneous populations expressing EGFRvIII from differentially edited *EGFR* genes. Those cells acquiring *EGFRvIII* are not only enhanced for aggressive tumor growth but also benefit surrounding cells without the *EGFR* mutation through paracrine effect.](oncotarget-10-2116-g001){#F1}

An important mechanistic question in this context involves the sequence of events that led to *EGFR* variant formation and *EGFR* amplification. Is extrachromosomal *EGFR* amplification a requisite precursor of *EGFRvIII?* For instance, this acquisition of glioblastoma specific *EGFR* deletion mutation might be associated with the fact that amplified *EGFR* in glioblastoma mostly resides in extrachromosomal DNA that is selectively captured in micronuclei \[[@R1]\], where complex DNA rearrangements take place \[[@R8]\]. In this way, extrachromosomal DNA generation possibly provides a path for the host cell to enhance malignant progression through micronuclei-mediated genomic rearrangements resulting in *EGFRvIII*.

Once *EGFRvIII* is formed, not only do cells expressing this mutant transform to a more aggressive phenotype as mentioned above, but surrounding tumor cells without mutant *EGFR* are also benefited in terms of growth and cell survival by paracrine effects through cytokines such as interleukin-6 \[[@R9]\], or through EGFR ligands such as heparin-binding EGF and transforming growth factor alpha \[[@R10]\] (Figure [1](#F1){ref-type="fig"}). Thus, tumors with subpopulations undergoing genomic rearrangements of amplified *EGFR* yielding *EGFRvIII* that establishes an ecosystem supportive of aggressive tumor growth. Elucidation of this mechanisms of further rearrangements of extrachromosomal amplicons should yield opportunities for future therapeutic development and mechanistic insight.
